Bevacizumab for Central Retinal Vein Occlusion Study

Phase 3

Completed

• Conditions: Central Retinal Vein Occlusion
• Interventions: Drug: bevacizumab; Drug: Sham bevacizumab injection

• Registration Number: NCT00906685
• Lead Sponsor: Anders Kvanta

Brief Summary

Central retinal vein occlusion is a leading cause of severe visual impairment. Until now, no treatment has been available to improve visual acuity. The present study intends to investigate if intravitreal bevacizumab can improve visual acuity as compared to sham-treated control patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-05
• Study First Submitted: 2009-05-20
• Study First Submitted QC: 2009-05-20
• Study First Posted: 2009-05-21
• Primary Completion: 2011-03
• Study Completion: 2011-09
• Status Verified: 2011-11
• Last Update Submitted: 2011-11-21
• Last Update Posted: 2011-11-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• CRVO with duration < 6 months
• Visual acuity of 20/800 to 20/50

Exclusion Criteria

• CRVO with duration of > 6 months
• previous treatment with anti-angiogenic drugs

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intravitreal bevacizumab	bevacizumab	-
Sham injection	Sham bevacizumab injection	-

Primary Outcome Measures

Name	Time	Method
The proportion of patients gaining 15 ETDRS letters or more	6 months

Secondary Outcome Measures

Name	Time	Method
Change in foveal thickness	6 months
Cases of neovascular glaucoma	6 months

Trial Locations

Locations (1)

St Eriks Eye Hospital; 🇸🇪 Stockholm, Sweden